Application of epibrassinolide in preparation of medicine for preventing or treating osteoporosis
The inhibition of osteoclast formation by epicarbazinolide has solved the problems of limited effects and toxic side effects of existing osteoporosis drugs, achieved effective prevention and treatment of osteoporosis, and provided a safe new drug choose.
Patent Information
- Application Number
- CN202310521080.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-09
- Publication Date
- 2024-11-19
AI Technical Summary
Existing drugs for the prevention and treatment of osteoporosis have limited effects on osteoporosis and have toxic side effects, especially bisphosphonates and denosumein gastrointestinal reactions and high prices.
Epirarasinolide is used to inhibit the differentiation of osteoclast precursor cells and the formation of osteoclasts. By inhibiting the differentiation of bone marrow-derived macrophages, it reduces or delays bone loss, prevents and treats osteoporosis.
Epirarasinolide significantly inhibits osteoclast formation, reduces or delays bone loss caused by estrogen deficiency, and provides a safe and effective new drug option for preventing and treating osteoporosis.
Smart Images

Figure CN118976033A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to use of epibrassinolide in preparing a medicine for preventing and / or treating osteoporosis. Background Art
[0002] 24-epibrassinolide, also known as 24-epibrassinolide (EBL), is a byproduct of brassinolide biosynthesis and has salt-tolerant biological activity. This compound is currently mainly used in the medical field for anti-cholesterol, anti-inflammatory, and anti-cancer purposes. The structure is shown below:
[0003]
[0004] Osteoporosis (OP) is a systemic bone disease that is caused by a variety of reasons, including decreased bone density, decreased bone quality, destruction of bone microstructure, increased bone brittleness, and prone to fractures. Osteoporosis generally occurs in postmenopausal women and elderly men, seriously affecting the patient's physical health and quality of life, and even shortening life expectancy and increasing family burden. It has become one of the key issues of social concern.
[0005] Bone tissue is always in the process of bone remodeling / bone turnover, where new bone replaces old bone. The "coupling" between the bone resorption of osteoclasts (OC) and the bone formation of osteoblasts (OB) constitutes the cellular basis of bone remodeling / bone turnover, while osteoporosis is the result of the "balance" process of bone remodeling / bone turnover tilting towards bone resorption [Dai Xiaoxia et al., Osteoporosis and Osteoclast Bone Resorption [J], Chinese Journal of Endemic Diseases, 2002(01):74-76; Wang Xiangfu et al., Research Progress on the Relationship between Osteoclasts and Osteoporosis [J], Chinese Journal of Osteoporosis, 2015, 021(011):1420-1424]. Based on this understanding, the research and development of drugs for the prevention or treatment of osteoporosis and the current first-line drugs in clinical practice are all osteoclast activity inhibitors [Lin Lingmin et al., Research Progress of Osteoporosis Therapeutic Drugs Targeting Osteoclasts [J], Chinese Journal of Minkang Medicine, 2015(14):200], such as bisphosphonates and the monoclonal antibody drug denosumab. Although a variety of drugs have been used to treat osteoporosis by inhibiting osteoclast formation in clinical practice, the effects of most drugs on osteoporosis are very limited, and some drugs have significant toxic side effects and many adverse reactions. For example, the utilization rate of bisphosphonates in the treatment of osteoporosis is low, and gastrointestinal reactions are prone to occur. Long-term use of such drugs can easily induce serious diseases such as esophageal cancer and mandibular osteonecrosis; denosumab cannot be widely used in clinical practice due to its high price.
[0006] Osteoclasts originate from bone marrow macrophages (BMMs) and are differentiated and activated to form mature osteoclasts under the regulation of cytokines such as macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL), which perform the function of bone resorption. Summary of the invention
[0007] The inventors of the present invention have found through research that epibrassinolide can inhibit the formation of osteoclasts and can be used as a new anti-osteoporosis drug.
[0008] According to one aspect of the present invention, there is provided a use of epibrassinolide in the preparation of a medicament for inhibiting the differentiation of osteoclast precursor cells.
[0009] According to the aforementioned use, the osteoclast precursor cells are bone marrow-derived macrophages (BMMs).
[0010] According to another aspect of the present invention, there is provided use of epibrassinolide in preparing a medicament for inhibiting osteoclast formation.
[0011] According to another aspect of the present invention, there is provided use of epibrassinolide in preparing a medicament for preventing and / or treating osteoporosis.
[0012] According to the aforementioned use, the epibrassinolide is used to inhibit the differentiation of osteoclast precursor cells or the formation of osteoclasts.
[0013] According to the aforementioned use, the osteoclast precursor cells are bone marrow-derived macrophages (BMMs).
[0014] According to the aforementioned use, the osteoporosis is osteoporosis caused by estrogen deficiency.
[0015] According to the present invention, epibrassinolide can inhibit the differentiation of osteoclast precursor cells, such as BMMs, or inhibit the formation of osteoclasts, thereby preventing and / or treating osteoporosis. In addition, OVX modeling experiments have shown that epibrassinolide can also reduce or delay bone loss caused by OVX. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The effect of epibrassinolide on BMMs differentiation (TRAP staining) is shown. Figure 1 Shown are microscopic images of osteoclast precursor BMMs after TRAP staining after treatment with different concentrations of drugs.
[0017] Figure 2 The number of osteoclasts formed by osteoclast precursor cell BMMs after drug treatment is shown, ***p<0.001, and there is a significant difference between the two groups as shown by the connecting line in the figure.
[0018] Figure 3 The graph shows the preventive effect of epibrassinolide on osteoporosis caused by estrogen deficiency (pq-CT). *p<0.1, ***p<0.001. There is a significant difference between the two groups as shown by the connecting line in the figure. DETAILED DESCRIPTION
[0019] The present invention is further described in the following examples, but the examples are not intended to limit the scope of protection of the present invention.
[0020] Example 1 Anti-osteoporosis effect
[0021] Epibrassinolide inhibits osteoclast differentiation and has preventive and therapeutic effects on osteoporosis caused by estrogen deficiency.
[0022] 1. Main experimental materials and instruments
[0023] Material Fetal bovine serum, α-MEM medium, 0.25% trypsin and penicillin / streptomycin were purchased from Gibco, tartrate-resistant acid phosphatase (TRAP) enzyme staining kit, DMSO, toluidine blue were purchased from sigma, CCK8 (cell proliferation and activity detection kit) was purchased from Dinjido, cytokines such as M-CSF and RANKL were purchased from novoprotein, PBS (phosphate buffered saline) was purchased from WISENT, epibrassinolide (EBL) was purchased from MCE, 4-week-old C57BL / 6 mice were purchased from Slack, and bone marrow-derived macrophages (BMMs) were obtained from the femoral and tibial medullary cavities of C57BL / 6 mice.
[0024] Instruments: CO2 incubator from Thermo scientific; inverted microscope from Olympus; microplate reader from Tecan.
[0025] 2. Experimental methods:
[0026] 1) Preparation of test cells:
[0027] C57BL / 6 mice were killed by cervical dislocation, disinfected by immersion in 75% alcohol, and the long bones of the limbs (femur and tibia) were stripped under sterile conditions. After removing the attached soft tissue, the bone marrow cavity was repeatedly rinsed with complete culture medium to completely remove the cells in the bone marrow cavity. The cell suspension was filtered with a cell sieve and cultured in a 10 cm cell culture dish. The next day, the supernatant cells were centrifuged, and the cells were suspended in complete culture medium supplemented with 30 ng / mL of M-CSF and re-cultured in a new 10 cm cell culture dish. Two days later, the attached BMMs were collected with a cell scraper, resuspended and quantitatively inoculated in a cell culture plate, cultured overnight under 5% CO2 and saturated humidity, and processed according to different experimental requirements the next day.
[0028] 2) Test of the effect of epibrassinolide on osteoclast formation (TRAP staining method):
[0029] Osteoclast precursor cell BMMs were seeded into 96-well plates at a concentration of 5000 cells / well and cultured overnight in proliferation medium (complete medium containing 30 ng / mL M-CSF). Different concentrations of epibrassinolide were prepared in induction medium (complete medium containing M-CSF (30 ng / mL) + RANKL (50 ng / mL)) to treat cells as experimental groups (i.e., epibrassinolide was prepared in induction medium containing 0.1% DMSO to a final concentration of 1 μmol / ml, 5 μmol / ml, and 10 μmol / ml, respectively, in experimental groups, i.e. Figure 1 1 micromolar group, 5 micromolar group and 10 micromolar group in the induction medium containing 0.1% DMSO as the control group (i.e. Figure 1 The cells were replaced with fresh culture medium every 2 days. After about 4-5 days, BMMs fused to form vesicular mature osteoclasts. The cells were removed, washed with PBS, fixed with 4% paraformaldehyde for 10 minutes, and then washed with PBS. TRAP staining solution was prepared according to the TRAP (tartrate-resistant acid phosphatase) staining kit, added to the cells, and placed at 37°C for about 1 hour. The cells were observed and photographed under an inverted microscope. The results are shown in Figure 1 , osteoclast-like cells with ≥3 nuclei were counted, and the results are shown in Figure 2 . Figure 1 It was shown that epibrassinolide inhibited the differentiation process of bone marrow osteoclast precursor cells BMMs into osteoclasts, as shown by a significant reduction in the number of osteoclasts.
[0030] 3) The preventive and therapeutic effects of epibrassinolide on osteoporosis caused by estrogen deficiency:
[0031] Method for establishing the model of osteoporosis (OVX) caused by estrogen deficiency in mice: Under sterile conditions, 8-week-old female mice were placed in a lateral position, long hair was plucked 2 cm on both sides of the spine and 1 cm below the ribs, and the skin was cut longitudinally on the back. Pink cauliflower-like ovaries the size of green beans were visible at the end of the Y-shaped uterus. The ovaries were ligated and removed, and the abdomen was sutured. For the sham operation group (SHAM) mice, the same position was cut, and the ovaries were not ligated and removed, but sutured. After the operation, the drug was administered for 6 consecutive weeks after the animal's physical fitness recovered. The SHAM group and the OVX group mice were given a solvent control (2.5% DMSO + 2.5% Tween 80 + 95% saline), and the OVX + EBL (3mg) group and the OVX + EBL (10mg) group were given 3mg and 10mg / kg of the drug (EBL) to the OVX model mice, respectively. Before administration, the brassinolide (EBL) was prepared into an injection solution with a solvent (2.5% DMSO + 2.5% Tween 80 + 95% saline), with 6 mice in each group, and the administration method was intraperitoneal administration. The injection volume of each group of mice was the same. After the administration, the femur of the animal was taken, fixed with 4% paraformaldehyde, and its bone density was detected.
[0032] Figure 3 The preventive effect of epibrassinolide on postmenopausal osteoporosis is shown.
[0033] The research results of the present invention show that epibrassinolide has a significant inhibitory effect on the differentiation of osteoclast precursor cells. TRAP reflects the metabolic activity of osteoclasts, so TRAP staining has become an important method for identifying osteoclasts. In order to evaluate the anti-osteoclast formation ability of epibrassinolide, the inventors incubated different doses of epibrassinolide with BMMs (while inducing them to differentiate into osteoclasts using M-CSF and RANKL), and after the osteoclasts differentiated and matured, TRAP staining was used to identify the number of osteoclasts formed. The results show that the epibrassinolide of the present invention inhibits the formation of osteoclasts in a dose-dependent manner, and has a very good inhibitory effect.
[0034] The research results of the present invention also confirm the preventive and therapeutic effects of epibrassinolide on postmenopausal osteoporosis. Osteoporosis caused by estrogen deficiency is one of the most common osteoporosis. Ovariectomy (OVX) in mice can well simulate osteoporosis caused by estrogen deficiency in women and is also the most commonly used animal model. Therefore, the inventors further studied the effect of epibrassinolide on osteoporosis caused by estrogen deficiency in mice. The results showed that epibrassinolide also protected against bone loss caused by OVX. Prevention of osteoporosis caused by estrogen deficiency ( Figure 3 ).
Claims
1. Use of epibrassinolide in the preparation of a medicament for inhibiting the differentiation of osteoclast precursor cells.
2. The use according to claim 1, in, The osteoclast precursor cells are bone marrow-derived macrophages.
3. Use of epibrassinolide in the preparation of a drug for inhibiting osteoclast formation.
4. Use of epibrassinolide in the preparation of a medicament for preventing and / or treating osteoporosis.
5. The use according to claim 4, in, The epibrassinolide is used for inhibiting the differentiation of osteoclast precursor cells or inhibiting the formation of osteoclasts.
6. The use according to claim 5, in, The osteoclast precursor cells are bone marrow-derived macrophages BMMs.
7. The use according to any one of claims 4 to 6, in, The osteoporosis is osteoporosis caused by estrogen deficiency.
